Researchers have revealed promising trial results indicating that taking 1,000 mg of vitamin C daily might help individuals with early-stage blood cancers and precancerous conditions experience fewer adverse effects and improved survival over several years.
- Vitamin C helped reduce adverse events in blood disorder patients
- Daily 1,000 mg doses linked to improved survival over three years
- Findings support further research with larger clinical trials
What happened
The phase 2 EVITA clinical trial tested the effects of daily oral vitamin C supplementation (1,000 mg) on patients with precancerous blood conditions such as clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndrome (MDS). The study involved 109 participants and employed a randomized, double-blind, placebo-controlled design to ensure reliable results. Over a year, those receiving vitamin C experienced fewer adverse health events and changes in immune signaling molecules linked to better disease outcomes.
Although vitamin C did not alter the progression rate of abnormal blood cells, an exploratory analysis revealed that participants who took vitamin C were significantly more likely to be alive after about three years compared to those who received a placebo. No participants were undergoing cancer treatment during the trial. These encouraging findings pave the way for more extensive phase 3 studies to firmly establish vitamin C’s potential role in managing early blood cancers.
Why it feels good
The possibility that such a common, accessible vitamin could improve outcomes in serious precancerous and early cancerous blood disorders offers hope for a simpler, less invasive way to support patients at risk of developing leukemia. Typically, options are limited for preventing progression to aggressive blood cancers, and some treatments can be too harsh or unsuitable for older adults who are most often affected.
By potentially reducing inflammation and restoring healthier immune system function at a cellular level through epigenetic mechanisms, vitamin C supplementation could represent an important step toward cancer interception — intervening early to change disease trajectory. Scientists involved express cautious optimism, emphasizing the importance of further research but hopeful that these findings may one day translate into better care and longer survival for vulnerable patients.
What to enjoy or watch next
The next critical step will be a larger phase 3 clinical trial to confirm these initial findings and to better understand exactly how vitamin C affects precancerous blood cells. Researchers at Van Andel Institute and collaborators around the world are planning this expanded study to validate the survival benefits and immune system changes observed in the current trial.
For those interested in advances in cancer prevention and supportive care, keeping an eye on emerging research into natural compounds like vitamin C offers a promising direction. News of trial results and expert updates will be valuable as the medical community continues to explore accessible, safe ways to improve outcomes for individuals with early signs of blood cancer.